Publications

Activity of the novel antimicrobial ceftolozane/tazobactam (CXA-201) tested against contemporary clinical strains from European hospitals, Lead author: Sader HS, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Antimicrobial activity of PTK 0796 (omadacycline) and comparator agents against contemporary pathogens commonly associated with community-acquired respiratory tract infections collected during 2011 from the European Union, Lead author: Flamm R, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Antimicrobial activity of PTK 0796 (omadacycline) tested against Gram-positive organisms isolated from European hospitals in 2011, Lead author: Sader HS, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

In vitro evaluation of antimicrobial spectrum and determination of optimal MIC test conditions for the novel protein epitope mimetics antibiotic POL7080, Lead author: Dale, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Spectrum and potency of ceftaroline against leading pathogens causing skin and skin-structure infections in Europe and South Africa, 2010, Lead author: Farrell DJ, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Ceftaroline activity against clinical isolates from United States hospitals: results from the 2011 Assessing Worldwide Antimicrobial Resistance Evaluation programme, Lead author: Sader HS, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Spectrum and potency of ceftaroline against leading pathogens causing community acquired respiratory tract infections in Europe and South Africa, 2010, Lead author: Farrell DJ, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Antimicrobial activity of ceftaroline and comparator agents against contemporary (2010) Streptococcus pneumoniae from Europe and South Africa, Lead author: Farrell DJ, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Characterisation of resistance mechanisms and epidemiology of Enterobacteriaceae collected during a phase II clinical trial for ceftazidime avibactam, Lead author: Mendes RE, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Prevalence of ESBL and carbapenemase-producing phenotypes of Enterobacteriaceae identified in the 2010 AWARE surveillance programme, Lead author: Krause, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Occurrence and genetic analysis of OXA-48-producing strains in European countries, 2007-2010, Lead author: Castanheira M, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Activity of ceftaroline tested against methicillin-resistant Staphylococcus aureus clones from Australia and New Zealand, 2010, Lead author: Bell JM, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Antimicrobial activity of ceftaroline and comparator agents against contemporary (2010) Staphylococcus aureus isolates from Europe and South Africa, Lead author: Farrell DJ, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Oritavancin activity tested against Staphylococcus aureus responsible for documented infections in European hospitals, Lead author: Mendes RE, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Update on daptomycin activity and spectrum tested against Gram-positive organisms collected in 2011 from European medical centres, Lead author: Sader HS, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Activity of JNJ-Q2 against Staphylococcus aureus isolated from patients with acute bacterial skin and skin structure infection obtained during a phase II clinical trial, Lead author: Farrell DJ, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Adjusting EUCAST zone diameter breakpoints for Haemophilus influenzae on the Mueller-Hinton Fastidious media, Lead author: Ahman, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Contemporary doxycyline and tetracycline susceptibility testing using CLSI and EUCAST criteria for Gram-positive pathogens: results from SENTRY programme, Lead author: Jones RN, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Activity of moxifloxacin tested against 14,930 clinical isolates of Enterobacteriaceae from Europe, Lead author: Farrell DJ, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Comparison of the Sensititre YeastOne colorimetric antifungal panel with CLSI microdilution for antifungal susceptibility testing of the echinocandins against Candida spp., using new clinical breakpoints and epidemiological cutoff values. by Pfaller MA, Chaturvedi V, Diekema DJ, Ghannoum MA, Holliday NM, Killian SB, Knapp CC, Messer SA, Miskou A and Ramani R published in Diagn. Microbiol. Infect. Dis. 2012; 73 (4): 365-368

Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. by Pfaller MA and Diekema DJ published in J. Clin. Microbiol. 2012; 50 (9): 2846-2856

Significance of molecular identification and antifungal susceptibility of clinically significant yeasts and moulds in a global antifungal surveillance program. by Pfaller MA, Woosley LN, Messer SA, Jones RN and Castanheira M published in Mycopathologia 2012; 174 (4): 259-271

Activity of JNJ-Q2 against Staphylococcus aureus isolated from patients with acute bacterial skin and skin-structure infection obtained during a Phase 2 clinical trial. by Farrell DJ, Turner LL, Castanheira M and Jones RN published in Diagn. Microbiol. Infect. Dis. 2012; 74 (1): 73-74

Activity of JNJ-Q2, a novel fluoroquinolone, tested against Neisseria gonorrhoeae, including ciprofloxacin-resistant strains. by Biedenbach DJ, Turner LL, Jones RN and Farrell DJ published in Diagn. Microbiol. Infect. Dis. 2012; 74 (2): 204-206

Molecular epidemiology of Staphylococcus epidermidis clinical isolates from USA hospitals. by Mendes RE, Deshpande LM, Costello A and Farrell DJ published in Antimicrob. Agents Chemother. 2012; 56 (9): 4656-4661

Multidrug resistance among Acinetobacter spp. in the USA and activity profile of key agents: Results from CAPITAL Surveillance 2010. by Queenan AM, Pillar CM, Deane J, Sahm DF, Lynch AS, Flamm RK, Peterson J and Davies TA published in Diagn. Microbiol. Infect. Dis. 2012; 73 (3): 267-270

Transferable plasmid-mediated resistance to linezolid due to cfr in a human clinical isolate of Enterococcus faecalis by Diaz L, Kiratisin P, Mendes R, Panesso D, Singh KV and Arias CA published in Antimicrob. Agents Chemother. 2012; 56 (7): 3917-3922

The PATH (Prospective Antifungal Therapy) alliance registry and invasive fungal infections: Update 2012. by Azie N, Neofytos D, Pfaller M, Meier-Kriesche HU, Quan SP and Horn D published in Diagn. Microbiol. Infect. Dis. 2012; 73 (4): 293-300

Caspofungin Etest susceptibility testing of Candida species: Risk of misclassification of susceptible isolates of C. glabrata and C. krusei when adopting the revised CLSI caspofungin breakpoints. by Arendrup MC and Pfaller MA published in Antimicrob. Agents Chemother. 2012; 56 (7): 3965-3968

Ceftaroline applications for therapy in the United States by Corey GR and Jones RN published in Clin. Infect. Dis. 2012; 55 (Suppl 3): S171-S172

Ceftaroline potency among 9 US census regions: Report from the 2010 AWARE program. by Flamm RK, Sader HS, Farrell DJ and Jones RN published in Clin. Infect. Dis. 2012; 55 (Suppl 3): S194-S205

AWARE ceftaroline surveillance program (2008-2010); Trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States. by Pfaller MA, Farrell DJ, Sader HS and Jones RN published in Clin. Infect Dis. 2012; 55 (Suppl 3): S187-S193

Activity of ceftaroline-avibactam tested against gram-negative organism populations, including strains expressing one or more beta-lactamases and methicillin-resistant Staphylococcus aureus carrying various SCCmec types. by Castanheira M, Sader HS, Farrell DJ, Mendes RE and Jones RN published in Antimicrob. Agents Chemother. 2012; 56 (9): 4779-4785

Activity analyses of staphylococcal isolates from pediatric, adult and elderly patients; AWARE ceftaroline surveillance program. by Sader HS, Flamm RK, Farrell DJ and Jones RN published in Clin. Infect. Dis. 2012; 55 (Suppl 3): S181-S186

In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: A review of published studies and the AWARE surveillance program (2008-2010). by Farrell DJ, Castanheira M, Mendes RE, Sader HS and Jones RN published in Clin. Infect. Dis. 2012; 55 (Suppl 3): S206-S214

Worldwide appraisal and update (2010) of telavancin activity tested against a collection of Gram-positive clinical pathogens from five continents. by Mendes RE, Sader HS, Farrell DJ and Jones RN published in Antimicrob. Agents Chemother. 2012; 56 (7): 3999-4004

Oritavancin microbiologic features and activity results from the surveillance program in the United States. by Mendes RE, Farrell DJ, Sader HS and Jones RN published in Clin. Infect. Dis. 2012; 54 (Suppl 3): S203-S213

Characterization of methicillin-resistant Staphylococcus aureus displaying increased MICs of ceftaroline. by Mendes RE, Tsakris A, Sader HS, Jones RN, Biek D, McGhee P, Appelbaum PC and Kosowska-Shick K published in J. Antimicrob. Chemother. 2012; 67 (6): 1321-1324

Comparison of Escherichia coli ST131 pulsotypes, by epidemiologic traits, 1967-2009. by Johnson JR, Nicolas-Chanoine MH, DebRoy C, Castanheira M, Robicsek A, Hansen G, Weissman S, Urban C, Platell J, Trott D, Zhanel G, Clabots C, Johnston BD and Kuskowski MA published in Emerg. Infect. Dis. 2012; 18 (4): 598-607

Challenges in assessing microbial susceptibility and predicting clinical response to newer-generation fluoroquinolones. by Segreti J, Jones RN and Bertino JS published in J. Ocul. Pharmacol. Ther. 2012; 28 (1): 3-11

Summary of ceftaroline activity against pathogens in the United States, 2010: Report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) Surveillance Program. by Flamm RK, Sader HS, Farrell DJ and Jones RN published in Antimicrob. Agents Chemother. 2012; 56 (6): 2933-2940

Antifungal drug resistance: Mechanisms, epidemiology, and consequences for treatment. by Pfaller MA published in Am. J. Med. 2012; 125 (1 Suppl): S3-S13

Oritavancin activity against vancomycin-susceptible and vancomycin-resistant enterococci with molecularly characterized glycopeptide resistance genes recovered from bacteremic patients, 2009-2010. by Mendes RE, Woosley LN, Farrell DJ, Sader HS and Jones RN published in Antimicrob. Agents Chemother. 2012; 56 (3): 1639-1642

Telavancin activity tested against a contemporary collection of Gram-positive pathogens from USA hospitals (2007-2009). by Mendes RE, Sader HS, Farrell DJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 2012; 72 (1): 113-117

Pharmacodynamics of beta-lactamase inhibition by NXL104 in combination with ceftaroline, examining organisms with multiple types of beta-lactamases. by Louie A, Castanheira M, Liu W, Grasso C, Jones RN, Williams G, Critchley I, Thye D, Brown D, Vanscoy B, Kulawy R and Drusano GL published in Antimicrob. Agents Chemother. 2012; 56 (1): 258-270

Synergistic activity of ceftobiprole and vancomycin in a rat model of infective endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus. by Fernandez J, Abbanat D, Shang W, He W, Amsler K, Hastings J, Queenan AM, Melton JL, Barron AM, Flamm RK and Lynch AS published in Antimicrob. Agents Chemother. 2012; 56 (3): 1476-1484

Expansion of clonal complex 258 KPC-2-producing Klebsiella pneumoniae in Latin American hospitals: Report of the SENTRY antimicrobial surveillance program. by Castanheira M, Costello AJ, Deshpande LM and Jones RN published in Antimicrob. Agents Chemother. 2012; 56 (3): 1668-1669

Evaluation of quinolone resistance-determining region mutations and efflux pump expression in Neisseria meningitidis resistant to fluoroquinolones. by Castanheira M, Deshpande LM, Jones RN and Farrell DJ published in Diagn. Microbiol. Infect. Dis. 2012; 72 (3): 263-266

Activities of E1210 and comparator agents tested by CLSI and EUCAST broth microdilution methods against Fusarium and Scedosporium species identified using molecular methods. by Castanheira M, Duncanson FP, Diekema DJ, Guarro J, Jones RN and Pfaller MA published in Antimicrob. Agents Chemother. 2012; 56 (1): 352-357

Antimicrobial activity of the investigational pleuromutilin compound BC-3781 tested against gram-positive organisms commonly associated with acute bacterial skin and skin structure infections. by Sader HS, Biedenbach DJ, Paukner S, Ivezic-Schoenfeld Z, Jones RN published in Antimicrob. Agents Chemother. 2012; 56 (3): 1619-1623